华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000963 华东医药

已收盘 02-11 15:00:00

{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":36.65,"timestamp":1770793386000,"preClose":36.72,"halted":0,"volume":5739156,"delay":0,"changeRate":-0.0019,"floatShares":1753000000,"shares":1754000000,"eps":2.1082,"marketStatus":"已收盘","change":-0.07,"latestTime":"02-11 15:00:00","open":36.6,"high":36.86,"low":36.51,"amount":211000000,"amplitude":0.0095,"askPrice":36.67,"askSize":2,"bidPrice":36.65,"bidSize":177,"shortable":0,"etf":0,"ttmEps":2.1082,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770859800000},"marketStatusCode":5,"adr":0,"adjPreClose":36.72,"symbolType":"stock","openAndCloseTimeList":[[1770773400000,1770780600000],[1770786000000,1770793200000]],"highLimit":40.39,"lowLimit":33.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1754021048,"isCdr":false,"pbRate":2.67,"roa":"--","peRate":17.384499,"roe":"11.39%","epsLYR":2.0046,"committee":-0.165217,"marketValue":64285000000,"turnoverRate":0.0033,"status":1,"floatMarketCap":64261000000},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2610060144","title":"华东医药：创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程","url":"https://stock-news.laohu8.com/highlight/detail?id=2610060144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610060144?lang=zh_cn&edition=full","pubTime":"2026-02-11 11:33","pubTimestamp":1770780797,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药02月10日在投资者关系平台上答复投资者关心的问题。为啥别人能做到一个接一个的大单华东医药回复：您好！创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程。公司始终秉持开放合作战略，在强化自主研发的同时，积极与全球同行一起探索创新药管线的BD机会。未来如达成明确合作协议，公司将严格按照信息披露规则履行披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100014208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","06978","BK0183","BK0187","BK0209","BK1574","BK0175","000963","BK0132","LU1969619763.USD","BK0196","BK0188","BK1161","159992"],"gpt_icon":0},{"id":"2608352978","title":"华东医药(000963.SZ)：DR10624注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608352978","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608352978?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:52","pubTimestamp":1770198775,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药(000963.SZ)公告，公司控股子公司浙江道尔生物科技有限公司(简称“道尔生物”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，由道尔生物申报的DR10624注射液临床试验申请已获得批准，可以开展临床试验，适应症为高甘油三酯血症(HTG)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华东医药(000963.SZ)：DR10624注射液临床试验申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0188","BK0175","000963","BK0196","BK0187","BK0209","LU2328871848.SGD","BK0183","LU1969619763.USD"],"gpt_icon":0},{"id":"2608352974","title":"华东医药最新公告：控股子公司获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608352974","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608352974?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:49","pubTimestamp":1770198597,"startTime":"0","endTime":"0","summary":"华东医药公告称，公司控股子公司道尔生物收到NMPA核准签发的《药物临床试验批准通知书》，由道尔生物申报的DR10624注射液临床试验申请已获得批准，可以开展临床试验，适应症为高甘油三酯血症。但需注意，药物在获得临床试验批准通知书后，尚需完成后续临床试验并经国家药品监督管理局审评、审批通过后方可上市，对公司近期业绩不会产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400030646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0183","LU1969619763.USD","BK0132","BK0196","LU2328871848.SGD","BK0188","BK0209","BK0175","BK0187"],"gpt_icon":0},{"id":"2608336199","title":"司美格鲁肽年销361亿美元，全球“药王”之战进入下半场","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336199","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608336199?lang=zh_cn&edition=full","pubTime":"2026-02-04 11:43","pubTimestamp":1770176580,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛报道2月3日，诺和诺德发布2025年财报。数据显示，诺和诺德全年营收3090.64亿丹麦克朗(约合489亿美元)，同比增长6%，净利润1024.34亿丹麦克朗(约合162亿美元)，同比 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20260204/c674539713.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20260204/c674539713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0132","BK0183","LU2580892789.USD","LU0405327148.USD","BK0188","BK0196","LU2148510915.USD","LU2097828557.USD","000963","LU1997244956.HKD","LU2580892862.HKD","LU2097828474.EUR","LU2097828631.EUR","LU1580142542.USD","LU1997245177.USD","LU1997245094.SGD","LU1655091616.SGD","600276","LU2328871848.SGD","LU0405327494.USD","LU1255011170.USD","LU1328615791.USD","BK0175","BK0012","BK0209","LU2289578879.USD","LU1781817850.SGD","LU1146622755.USD","LU1064130708.USD","LU2097828714.EUR","BK0239","BK0028","LU2097828805.USD","LU2495084118.USD","LU2488822045.USD","LU1969619763.USD","BK0187","LU1064131003.USD","BK0060","LU1820825898.SGD"],"gpt_icon":1},{"id":"2608822944","title":"华东医药最新公告：全资子公司收到罗氟司特乳膏上市许可申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822944","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608822944?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:30","pubTimestamp":1770114603,"startTime":"0","endTime":"0","summary":"华东医药公告称，全资子公司中美华东收到国家药品监督管理局签发的《受理通知书》，罗氟司特乳膏0.05%上市许可申请获得受理，申报适应症为适用于2岁至5岁轻度至中度特应性皮炎患者的局部外用治疗。该药物是中美华东与美国Arcutis Biotherapeutics, Inc.合作引进的创新皮肤外用制剂产品，中美华东拥有在大中华区及东南亚的独家权益。罗氟司特乳膏0.05%相比传统治疗手段有安全性优势，且可用于所有部位，每日一次给药，提高治疗依从性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300033166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0196","LU2328871848.SGD","BK0175","BK0188","BK0183","BK0132","000963","BK0209","BK0187"],"gpt_icon":0},{"id":"2607093966","title":"185亿美元合作落地！石药集团牵手阿斯利康竞逐减重市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2607093966","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607093966?lang=zh_cn&edition=full","pubTime":"2026-01-30 13:52","pubTimestamp":1769752320,"startTime":"0","endTime":"0","summary":"1月30日开盘前，石药集团（1093.HK）公告称，已与阿斯利康签署战略研发合作与授权协议。双方将依托石药集团专有的缓释给药技术平台及多肽药物AI发现平台，联合开发创新长效多肽药物。本次合 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260130/c674429187.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260130/c674429187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU0405327148.USD","BK0188","LU2097828474.EUR","BK0012","600276","BK0196","LU2328871848.SGD","LU1997245094.SGD","BK0132","LU1580142542.USD","LU1997244956.HKD","LU1655091616.SGD","LU1969619763.USD","LU2289578879.USD","LU0405327494.USD","LU1820825898.SGD","LU1255011170.USD","LU2488822045.USD","LU1997245177.USD","LU1781817850.SGD","LU2097828631.EUR","LU1064131003.USD","BK0060","BK0209","LU1064130708.USD","BK0175","BK0187","LU2580892789.USD","000963","LU1146622755.USD","BK0183","LU2097828714.EUR","LU1328615791.USD","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","LU2097828557.USD","BK0028","BK0239","LU2580892862.HKD"],"gpt_icon":0},{"id":"2607709021","title":"华东医药：公司生产经营一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2607709021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607709021?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:18","pubTimestamp":1769674694,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药01月29日在投资者关系平台上答复投资者关心的问题。公司管理层是否重视此类情况，并积极采取措施应对。根据我们的监测，公司连续20个交易日内股票收盘价格累计波动幅度并未触及您所提及的阈值。尽管如此，公司管理层始终高度重视公司在资本市场的表现以及全体股东的利益。目前，公司生产经营一切正常，核心业务稳步推进，研发管线也按计划取得进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900025568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0183","BK0209","BK0187","BK0188","000963","BK0175","BK0132","LU2328871848.SGD","BK0196"],"gpt_icon":0},{"id":"2606427195","title":"华东医药：持续聚焦主业创新与经营优化","url":"https://stock-news.laohu8.com/highlight/detail?id=2606427195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606427195?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:33","pubTimestamp":1769484803,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药01月26日在投资者关系平台上答复投资者关心的问题。光说不练吗华东医药回复：您好！公司管理层始终密切关注市值表现，并深切理解投资者的期待与关切。市值波动受宏观环境、行业周期及市场情绪等多重因素影响，但管理层始终将提升公司内在价值作为核心要务。我们持续聚焦主业创新与经营优化，通过强化研发管线、推进国际化合作及提升运营效率，夯实长期发展基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700016126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0196","BK0187","BK0132","BK0175","BK0183","BK0188","BK0209","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2606616271","title":"华东医药：HDM1002作为具有差异化的口服GLP-1靶向药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2606616271","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606616271?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:33","pubTimestamp":1769484796,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药01月26日在投资者关系平台上答复投资者关心的问题。公司认为 HDM1002 的产品特性，对于拥有成熟糖尿病销售网络但缺乏核心 GLP-1 管线的跨国药企，是否具备极强的战略互补价值？HDM1002作为具有差异化的口服GLP-1靶向药物，其定位正是为了满足全球市场未满足和差异化的临床需求。公司始终秉持开放合作战略，在强化自主研发的同时，积极与全球同行一起探索创新药管线的BD机会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700016115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0175","000963","LU1969619763.USD","BK0187","BK0196","BK0188","LU2328871848.SGD","BK0183","BK0132"],"gpt_icon":0},{"id":"2603694041","title":"华东医药最新公告：控股子公司DR10624注射液获得美国FDA新药临床试验批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2603694041","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603694041?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:19","pubTimestamp":1768385983,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司控股子公司浙江道尔生物科技有限公司收到美国FDA通知，由道尔生物申报的DR10624注射液药品临床试验申请已获得美国FDA批准，可在美开展临床试验，适应症为代谢相关脂肪性肝病（MASLD）。DR10624是道尔生物自主研发的全球首创的靶向FGF21R、GCGR和GLP-1R的长效三特异性激动剂。该药物已成功完成重度高甘油三酯血症的Ⅱ期临床研究并获得阳性顶线结果。此次获得临床试验批准，对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400032214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","LU1969619763.USD","BK0175","BK0183","BK0132","LU2328871848.SGD","BK0196","BK0209","000963","BK0188"],"gpt_icon":0},{"id":"2601006328","title":"股市必读：华东医药（000963）1月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601006328","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601006328?lang=zh_cn&edition=full","pubTime":"2026-01-08 01:08","pubTimestamp":1767805693,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，华东医药报收于39.16元，下跌1.06%，换手率0.54%，成交量9.53万手，成交额3.76亿元。投资者： 关注到公司正在推进 HDM7006 的注册申报工作。Biomee#1 和Biomee#2 乳膏目前尚未在海外上市。上述产品在国内将作为进口化妆品进行注册备案，而非药品的注册审批路径，无需在国内开展临床试验。交易信息汇总资金流向1月7日主力资金净流出2410.91万元；游资资金净流入2358.64万元；散户资金净流入52.27万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800000608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0187","LU1969619763.USD","BK0188","BK0175","BK0183","BK0132","BK0209","BK0196","000963"],"gpt_icon":0},{"id":"2601731358","title":"华东医药：Biomee®#1和Biomee®#2乳膏尚未海外上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601731358","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601731358?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:30","pubTimestamp":1767774638,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药01月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，公司2026年签下的第一个商业化项目 MC2的皮肤学级护肤乳膏Biomee#1和Biomee#2乳膏，这两个产品目前在国外上市了吗？公司的公告太简单，所以请求公布更多关于该项目的信息。Biomee#1 和Biomee#2 乳膏目前尚未在海外上市。上述产品在国内将作为进口化妆品进行注册备案，而非药品的注册审批路径，无需在国内开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700022856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0188","BK0175","000963","BK0196","BK0187","BK0209","LU2328871848.SGD","BK0183","LU1969619763.USD"],"gpt_icon":0},{"id":"2601878065","title":"华东医药：具体营收利润测算属内部敏感信息不便披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2601878065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601878065?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:27","pubTimestamp":1767774425,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药01月07日在投资者关系平台上答复投资者关心的问题。投资者提问：关注到公司正在推进 HDM7006 的注册申报工作。请问结合当前临床进展及市场评估，公司是否对该产品未来上市后的 预期营收规模及净利润贡献进行了测算或内部评估？公司内部虽会进行必要的市场分析与评估，但具体的营收、利润测算及关键商业假设属于公司未公开的内部敏感信息，不便对外披露，请予理解。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700022460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963"],"gpt_icon":0},{"id":"2595716668","title":"佐力药业，被700亿华东医药“追堵”","url":"https://stock-news.laohu8.com/highlight/detail?id=2595716668","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595716668?lang=zh_cn&edition=full","pubTime":"2025-12-31 00:24","pubTimestamp":1767111866,"startTime":"0","endTime":"0","summary":"文｜《投资者网》蔡俊最近，佐力药业不平静。外部，华东医药与公司的诉讼暂告段落，但还未迎来终局。其实，华东医药起诉的核心是与公司争夺百令系列产品。截至目前，公司、华东医药的市值分别约120亿元、700亿元。留“后手”+再造新曲线几乎在收购未来生物的同期，佐力药业与华东医药发布纠纷进展。根据公告，法院驳回华东医药子公司的全部诉讼请求，并要求其负担案件受理费。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1766906460012125486","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0209","BK0175","000963","BK0239","LU1969619763.USD","BK0187","BK0196","BK0077","BK0188","300181","LU2328871848.SGD","BK0183","BK0042","BK0132"],"gpt_icon":0},{"id":"2595763376","title":"华东医药：创新转型进入密集收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2595763376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595763376?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:34","pubTimestamp":1767065645,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药12月29日在投资者关系平台上答复投资者关心的问题。真是为公司捏把汗呀 老师是了解全面状况的 盼陈老师给这些老股东们一个实底就好了 谢谢华东医药回复：您好！创新转型一直是公司的核心战略方向。对于创新药业务收入，公司具备充分的战略信心与执行保障，目前公司已将资源配置、考核机制全面向创新业务倾斜，管理层及全体员工均已明确目标、凝聚共识。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000016092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","BK0196","LU2328871848.SGD","000963","LU1969619763.USD","BK0175","BK0187","BK0209","BK0132"],"gpt_icon":0},{"id":"2595727323","title":"股市必读：华东医药（000963）12月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595727323","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595727323?lang=zh_cn&edition=full","pubTime":"2025-12-29 01:38","pubTimestamp":1766943491,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，华东医药报收于39.7元，下跌0.82%，换手率0.27%，成交量4.74万手，成交额1.89亿元。董秘最新回复投资者： 您好，请问截止到2025年12月24日公司股东数是多少？此外，公司也可在严格核实股东身份信息后按相关规定告知。联系电话：0571-89903300，公司邮箱：ir@eastchinapharm.com。当日关注点来自交易信息汇总：12月26日主力资金净流出2005.09万元，显示主力短期内可能持谨慎态度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900000575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0188","BK0183","BK0132","LU1969619763.USD","000963","BK0196","BK0209","BK0175","BK0187"],"gpt_icon":0},{"id":"2593423049","title":"华东医药：4mg组疗效略优于2mg组","url":"https://stock-news.laohu8.com/highlight/detail?id=2593423049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593423049?lang=zh_cn&edition=full","pubTime":"2025-12-24 11:37","pubTimestamp":1766547457,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药12月23日在投资者关系平台上答复投资者关心的问题。HDM1005目前的二期数据展示的是实测值，在经过治疗组、基线体重等影响因素校正后 4mg 组疗效略优于 2mg 组；同时，二期治疗时间短，且需要从低剂量逐渐滴定至目标剂量，稳定治疗时长较短是 2mg 和 4mg 疗效接近的主要原因。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400014706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0196","BK0209","BK0175","LU1969619763.USD","BK0187","BK0132","BK0188","000963","BK0183"],"gpt_icon":0},{"id":"2591616710","title":"华东医药：HDM1002减重效果呈剂量依赖性","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616710?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:15","pubTimestamp":1765786516,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药12月15日在投资者关系平台上答复投资者关心的问题。HDM1002减重Ⅱ期临床研究结果显示，HDM1002 100 mg BID组、HDM1002 200 mg BID组、HDM1002 400 mg QD组及安慰剂组给药12周后体重较基线变化百分比分别为-4.63%、-6.08%、-6.83%和-2.88%。从Ⅱ期数据来看，HDM1002体重降低的效果呈现剂量依赖性，随着剂量的增加，减重效应也随之提升；HDM1002 12周减重未达到平台期，体重下降的趋势仍然明显，且随着用药时间的延长，各剂量组的减重效果均有进一步提升的潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500015748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0132","BK0183","LU2328871848.SGD","BK0188","LU1969619763.USD","BK0196","BK0187","000963","BK0175"],"gpt_icon":0},{"id":"2591616160","title":"华东医药：利那拉生酯进入2025年国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616160","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616160?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:00","pubTimestamp":1765785626,"startTime":"0","endTime":"0","summary":"利那拉生酯是生诺医药与Cinclus Pharma合作开发的新一代钾离子竞争性酸阻滞剂类药物，用于治疗消化系统疾病，目前，该药物针对反流性食管炎适应症已在国内获批并成功进入2025年国家医保目录。根据协议条款，生诺医药作为MAH持有人，负责利那拉生酯的研发、注册、生产和供应，在协议签署并生效后，生诺医药将获得首付款，以及相应里程碑付款；公司将负责利那拉生酯在中国大陆的商业化推广工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500014168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","LU1969619763.USD","BK0175","BK0183","BK0132","LU2328871848.SGD","BK0196","BK0209","000963","BK0188"],"gpt_icon":0},{"id":"2591261616","title":"华东医药：爱拉赫未进医保因成本与支付标准存差距","url":"https://stock-news.laohu8.com/highlight/detail?id=2591261616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591261616?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:00","pubTimestamp":1765785623,"startTime":"0","endTime":"0","summary":"今年公司两大王牌新药，利纳西普因为备货问题还未上市，爱拉赫未进医保，公司内部是否有些问题，领导怎么看？爱拉赫作为公司引进的进口创新药产品，没有被纳入2025年国家医保目录的主要原因是，目前其综合成本及海外市场价格与国内医保支付标准之间尚存在差距。此外，爱拉赫中国市场包装版本已于11月初正式商业化并开出全国首张处方。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500014165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","LU1969619763.USD","BK0175","BK0183","BK0132","LU2328871848.SGD","BK0196","BK0209","000963","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770810360933,"stockEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":-0.0734},{"period":"3month","weight":-0.1421},{"period":"6month","weight":-0.1347},{"period":"1year","weight":0.0808},{"period":"ytd","weight":-0.0692}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0019},{"period":"3month","weight":0.0321},{"period":"6month","weight":0.126},{"period":"1year","weight":0.2427},{"period":"ytd","weight":0.0402}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"68793人(较上一季度减少1.50%)","perCapita":"25487股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175402万元","survey":"　　华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司凭借优秀的ESG治理能力，WINDESG评级从A级提升至AA级，此外，公司目前MSCIESG评级A级，深交所国证ESG评级AA级，并且获得2024《新财富》杂志“ESG最佳实践”,E药经理人“2025生物医药可持续价值领航奖”等荣誉。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}